Westfield Capital Management Co. LP Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Key Points

• Westfield Capital Management Co. LP increased its stake in MoonLake Immunotherapeutics by 9.4%, owning 1,434,770 shares valued at approximately $56 million.
• Institutional investors collectively own 93.85% of MoonLake Immunotherapeutics, with several firms significantly increasing their positions in the last quarter.
• Analysts have a consensus rating of Moderate Buy for the stock, with a target price averaging $73.14.

Westfield Capital Management Co. LP raised its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,434,770 shares of the company's stock after buying an additional 123,151 shares during the quarter. Westfield Capital Management Co. LP owned about 2.24% of MoonLake Immunotherapeutics worth $56,056,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Deutsche Bank AG boosted its stake in MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after buying an additional 338 shares during the period. US Bancorp DE boosted its stake in shares of MoonLake Immunotherapeutics by 114.4% during the first quarter. US Bancorp DE now owns 2,208 shares of the company's stock valued at $86,000 after purchasing an additional 1,178 shares during the period. Birchview Capital LP purchased a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter valued at $217,000. KLP Kapitalforvaltning AS bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at about $244,000. Finally, PEAK6 LLC bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at about $271,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on MLTX shares. Wedbush restated an "outperform" rating and issued a $80.00 price objective (up from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price for the company in a report on Monday, May 19th. Rothschild & Co Redburn assumed coverage on shares of MoonLake Immunotherapeutics in a report on Monday, July 28th. They issued a "neutral" rating and a $65.00 target price for the company. Finally, The Goldman Sachs Group upped their price objective on shares of MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $74.43.

MoonLake Immunotherapeutics Price Performance

NASDAQ MLTX traded down $0.87 during trading hours on Thursday, reaching $51.89. The stock had a trading volume of 296,159 shares, compared to its average volume of 537,532. The stock has a fifty day moving average of $48.60 and a 200 day moving average of $43.12. MoonLake Immunotherapeutics has a 52-week low of $31.42 and a 52-week high of $58.26. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 21.11.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period last year, the firm posted ($0.39) earnings per share. Research analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.